Abbreviations {#nomen0010}
=============

MD

:   mammographic density

BC

:   breast cancer

BI-RADS

:   Breast Imaging-Reporting and Data System

MRI

:   magnetic resonance imaging

NACT

:   neoadjuvant chemotherapy

pCR

:   pathological complete response

FEC

:   fluorouracil, epirubicin and cyclophosphamide

EC

:   epirubicin and cyclophosphamide

HER2

:   human epidermal growth factor receptor 2

ALN

:   axillary lymph node

ER

:   estrogen receptor

PR

:   progesterone receptor

VBD%

:   volumetric breast density percentage

FGV

:   fibroglandular volume

IQR

:   interquartile range

OR

:   odds ratio

BMI

:   body mass index

DCIS

:   ductal carcinoma in situ

1. Introduction {#sec1}
===============

Mammographic density (MD) has gained significant interest and publicity in breast cancer (BC) screening. This is because women within the highest density categories have up to a 4- to 6-fold increased risk of primary BC in comparison to women with non-dense breasts \[[@bib1]\]. The role of MD as a predictive marker in terms of response to diverse oncological treatments is less studied although it has been shown that a decrease in MD during tamoxifen treatment---both in the primary and secondary preventive setting---is associated with risk reduction for BC and recurrence hereof \[[@bib2],[@bib3]\].

As a complement or alternative to the subjective Breast Imaging-Reporting and Data System (BI-RADS) categorization \[[@bib4]\], assessment of MD can be estimated by one of many software products operating on both digital vendor-processed and unprocessed mammograms. Validated against BI-RADS and magnetic resonance imaging (MRI) \[[@bib5],[@bib6]\], Volpara™ is robust and consistent across manufacturers \[[@bib7],[@bib8]\] for measurement of volumetric MD.

On the tissue level, high MD represents a proliferative and pro-inflammatory environment \[[@bib9],[@bib10]\]. It is plausible that the same biological mechanisms associated with tumor initiation and tumor growth in dense breasts may be responsible for a poorer treatment response. Previous studies including one from our group \[[@bib11],[@bib12]\], have shown that patients with high MD are less responsive to neoadjuvant chemotherapy (NACT) in terms of pathological complete response (pCR)---a surrogate marker for long-term survival \[[@bib13],[@bib14]\]. However, both previous studies were retrospective and used only a qualitative method for MD assessment (Wolfe categorization \[[@bib15]\] and BI-RADS, respectively). Biomarkers, including imaging biomarkers, are needed for more personalized oncological treatment. This study aimed to investigate whether MD assessed with a volumetric quantitative method or a change in MD during NACT for BC is a predictive marker for pCR.

2. Material and methods {#sec2}
=======================

2.1. Cohort and clinical parameters {#sec2.1}
-----------------------------------

From 2014 to 2019, we included 207 BC patients assigned to NACT within the ongoing SCAN-B trial (Clinical Trials ID NCT02306096) at Skåne University Hospital, Sweden \[[@bib16],[@bib17]\]. Patients were enrolled at their first visit to the Department of Oncology following their BC diagnosis. The inclusion criteria were female, age ≥18 years, accepting NACT, and ability to give informed written consent. Reasons for exclusion (N = 7) are presented in [Fig. 1](#fig1){ref-type="fig"}. Bilateral mammograms and unilateral ultrasound of the cancerous breast and axilla were performed at baseline and after two and six cycles of chemotherapy, respectively ([Fig. 2](#fig2){ref-type="fig"}).Fig. 1Patient flow chart.Fig. 1Fig. 2Study timeline.Fig. 2

Patients received NACT according to the same guidelines and standard treatment included three series of fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) followed by three series of docetaxel. HER2 double-blockade (trastuzumab and pertuzumab) was provided for human epidermal growth factor receptor 2 (HER2)-overexpression concomitantly with NACT. Ninety-seven percent of the patients received standard NACT, and 3% (N = 6) of the patients received a taxane-only NACT-regimen, and one patient received EC only. Among the patients with HER2-overexpressing tumors (N = 48), 94% received a double HER2-blockade whereas the remainder received only trastuzumab.

Clinical data and information on potential confounders were retrieved from patient questionnaires regarding anthropometrics, lifestyle factors, reproductive and hormonal history, previous breast disorders, and current and previous use of prespecified pharmaceuticals. Menopausal status at the time of diagnosis was defined according to self-reported menstrual history and patients with more than 1 year since the last period (secession of periods not caused by birth control, i.e., intrauterine hormonal contraceptive, or recent pregnancy/breastfeeding) were considered postmenopausal. Information on tumor characteristics was retrieved from clinical pathology reports. A pCR was defined as the absence of any residual invasive cancer in the resected breast after surgery as well as all sampled axillary lymph nodes (ALN) following completion of NACT \[[@bib18]\]. For the four patients with bilateral BC, the breast with the largest tumor/tumors was followed and evaluated. The Research Electronic Data Capture application was used for secure data entry \[[@bib19]\]. The study was approved by the Regional Ethics Committee in Lund, Sweden (committee's reference numbers: 2014/13, 2014/521, and 2016/521).

2.2. Digital mammography {#sec2.2}
------------------------

Through prospectively collected radiological study forms (Supplementary Material 1), detailed radiological tumor characteristics were retrieved and noted in real-time at the examination. Clinical bilateral digital mammograms in three views were acquired on different machines: GE Senographe Pristina (3%), Philips MammoDiagnost DR (17%), Philips MicroDose (2%), and Siemens Mammomat Inspiration (77%). All images were saved in their raw, unprocessed format, and MD was estimated with the computerized fully-automatic software Volpara™ (version 1.5.4.0, Volpara Solutions Limited, Wellington, New Zealand) for which technical details are described elsewhere \[[@bib20]\]. Briefly, the volumetric estimate is derived from a 2-dimensional digital mammogram that creates an artificial volume based on assumptions of the anatomy of the breast, knowledge of the breast thickness, and image processing \[[@bib20]\]. Volumetric breast density percentage (VBD%) is a continuous variable calculated as the ratio of absolute dense tissue volume \[fibroglandular volume (FGV)\] to total breast volume. At each time point, the craniocaudal view and the mediolateral oblique view in both breasts and the contralateral healthy breast only, respectively, were used to calculate MD (VBD% and FGV). In line with a previous study showing good concordance in MD between the ipsilateral tumorous breast and the contralateral healthy breast \[[@bib21]\], a simplified validation was performed showing no large difference in volumetric MD in cancer affected and non-affected breast supporting the use of the average VBD%~bilat~ in the descriptive statistics. Experienced breast radiologists, in direct connection to the examination, assessed the MD of the contralateral breast according to BI-RADS 5th edition \[[@bib4]\].

2.3. Statistical analysis {#sec2.3}
-------------------------

We first plotted the cumulative distribution of the mean of the VBD% in both breasts (VBD%~bilat~) within each BI-RADS level. We also plotted the change in VBD%~bilat~ from baseline to T1 (after 2nd chemotherapy cycle) and from baseline to T2 (after 6th chemotherapy cycle) versus baseline VBD%~bilat~; equivalent plots were made with the mean of FGV in both breasts (FGV~bilat~) instead of VBD%~bilat~.

Next, patient characteristics were summarized by the BI-RADS level at baseline. Categorical variables were described by counts and percentages whereas continuous variables were described by their median and interquartile range (IQR). For categorical variables, we furthermore assessed the median and IQR of baseline VBD%~bilat~ within each level of the variable. Finally, we described the baseline characteristics and VBD%~bilat~ at T1 and T2 of the patients by pCR status at the end of the follow-up.

We then set up logistic regression models including either VBD%~bilat~, the VBD% of the contralateral non-cancer affected breast only (VBD%~contra~), FGV~bilat~, or BI-RADS as the independent variable. pCR was the dependent (outcome) variable. We also considered dynamic models, i.e., models in which absolute change in MD from T0 to T1 \[i.e., VBD% (at T1) minus VBD% (at T0)\], T0 to T2, and T1 to T2, respectively, served as independent variables. For both VBD%~bilat~ and VBD%~contra~, we established models with an odds ratio (OR) corresponding to a 0.3, 0.5, and 2.0 percentage point change in VBD%, respectively. In addition, models based on relative change (OR corresponding to 5% change) in VBD%~bilat~ as the independent variable were established. For FGV~bilat~, we built the models with an OR corresponding to a 1- and 3-unit change, respectively. In the logistic regression models, we used generalized estimating equations to consider within-hospital site correlations. We set up both crude models and partially- and fully adjusted models. In the partially adjusted models, we included age, body mass index (BMI), menopausal status, parity and hormone replacement therapy; in the fully adjusted models, we also included ER, Ki67, HER2, ALN status, and tumor size at diagnosis. In the dynamic models, we also adjusted for MD at baseline and T1 because a decrease in MD was mostly seen in patients with high MD at baseline. Finally, similar logistic regression models were used to analyze the cohorts within subgroups defined by ALN, ER, and menopausal status. All analyses were carried out in SAS (SAS Institute Inc., Version 9.4, Cary, NC, USA).

3. Results {#sec3}
==========

The distribution of baseline characteristics according to BI-RADS and VBD%~bilat~ is presented in [Table 1](#tbl1){ref-type="table"} for the 200 BC patients receiving NACT ([Fig. 1](#fig1){ref-type="fig"}). For the whole cohort, the median age was 53.1 years (IQR 45.9 to 62.5), the median BMI was 25.6 (IQR 22.4 to 28.7), median VBD%~bilat~ at diagnosis was 11.0 (IQR 7.5 to 17.1), and median FGV~bilat~ was 73.5 cm^3^ (IQR 52.4 to 100).Table 1Patient and tumor characteristics according to mammographic density at diagnosis.Table 1BI-RADS a (N = 9)BI-RADS b (N = 74)BI-RADS c (N = 90)BI-RADS d (N = 27)VBD%~bilat~ median (IQR)Age at diagnosisMedian (IQR)62 (58--67)56 (46--65)51 (44--62)47 (43--60)BMIMedian (IQR)34.0 (28.7--36.8)26.5 (22.4--28.7)24.8 (22.3--28.7)23.9 (22.1--25.6)Age at menarcheMedian (IQR)13 (11--14)13 (12--14)13 (12--14)13 (12--13)MissingN = 50 (0.0)1 (1.4)4 (4.4)0 (0.0)Menopausal statusPremenopausalN = 950 (0)28 (37.8)51 (56.7)16 (59.3)14.0 (10.0--19.6)PostmenopausalN = 1059 (100)46 (62.2)39 (43.3)11 (40.7)8.3 (5.7--12.6)Number of pregnanciesNoneN = 190 (0)6 (8.1)10 (11.1)3 (11.1)12.0 (6.0--20.1)1N = 281 (11.1)11 (14.9)10 (11.1)6 (22.2)10.7 (8.5--17.8)2N = 760 (0)26 (35.1)40 (44.4)10 (37.0)12.4 (7.7--17.8)3+N = 778 (88.9)31 (41.9)30 (33.3)8 (29.6)9.8 (6.9--15.0)Any live birthNoN = 311 (11.1)9 (12.2)15 (16.7)6 (22.2)12.8 (7.1--18.5)YesN = 1698 (88.9)65 (87.8)75 (83.3)21 (77.8)11.0 (7.6--16.7)Age first birth (years)No childrenN = 311 (11.1)9 (12.2)15 (16.7)6 (22.2)12.8 (7.1--18.5)\<20N = 102 (22.2)4 (5.4)4 (4.4)0 (0)8.6 (5.8--10.0)20--29N = 906 (66.7)33 (44.6)40 (44.4)11 (40.7)10.1 (6.6--16.9)30--34N = 440 (0)15 (20.3)22 (24.4)7 (25.9)13.3 (9.6--19.0)35+N = 210 (0)11 (14.9)7 (7.8)3 (11.1)10.0 (8.7--15.6)MissingN = 40 (0)2 (2.7)2 (2.2)0 (0)8.5 (6.9--10.4)Number of biological childrenNoneN = 311 (11.1)9 (12.2)15 (16.7)6 (22.2)12.8 (7.1--18.5)1N = 340 (0)16 (21.6)14 (15.6)4 (14.8)9.5 (7.9--12.7)2N = 963 (33.3)33 (44.6)47 (52.2)13 (48.1)11.7 (7.7--17.4)3+N = 395 (55.6)16 (21.6)14 (15.6)4 (14.8)9.6 (6.4--16.7)Alcohol use once a week or more oftenYesN = 923 (33.3)34 (45.9)42 (46.7)13 (48.1)11.2 (7.7--18.0)NoN = 1076 (66.7)40 (54.1)47 (52.2)14 (51.9)10.4 (7.2--16.5)MissingN = 10 (0)0 (0)1 (1.1)0 (0)17.1 (17.1--17.1)ExerciseMore than 4 h/weekN = 642 (22.2)23 (31.1)31 (34.4)8 (29.6)12.0 (7.9--15.7)Less than 4 h/weekN = 1005 (55.6)34 (45.9)44 (48.9)17 (63.0)11.8 (7.6--18.9)NothingN = 342 (22.2)16 (21.6)14 (15.6)2 (7.4)8.9 (6.1--11.8)MissingN = 20 (0)1 (1.4)1 (1.1)0 (0)10.0 (5.7--14.3)SmokingCurrentN = 192 (22.2)8 (10.8)8 (8.9)1 (3.7)8.7 (5.8--10.8)FormerN = 673 (33.3)24 (32.4)30 (33.3)10 (37.0)10.1 (6.4--16.6)NeverN = 1144 (44.4)42 (56.8)52 (57.8)16 (59.3)12.3 (8.3--17.5)Ever hormone replacement therapyYesN = 180 (0)7 (9.5)8 (8.9)3 (11.1)11.0 (8.6--18.4)NoN = 1829 (100)67 (90.5)82 (91.1)24 (88.9)11.1 (7.4--16.9)Oral contraceptivesCurrentN = 50 (0)1 (1.4)2 (2.2)2 (7.4)14.1 (13.1--14.3)FormerN = 1465 (55.6)50 (67.6)72 (80.0)19 (70.4)12.3 (7.9--18.0)NeverN = 484 (44.4)22 (29.7)16 (17.8)6 (22.2)8.7 (5.9--12.0)MissingN = 10 (0)1 (1.4)0 (0)0 (0)5.7 (5.7--5.7)Tumor size at diagnosis (mm)[a](#tbl1fna){ref-type="table-fn"}Median (IQR)34 (26--40)27 (21--38)30 (21--40)36 (23--42)MissingN = 30 (0.0)1 (1.4)2 (2.2)0 (0.0)Estrogen receptor statusPositive (≥10%)N = 1215 (55.6)45 (60.8)52 (57.8)19 (70.4)11.2 (7.6--16.7)Negative (\<10%)N = 794 (44.4)29 (39.2)38 (42.2)8 (29.6)10.9 (7.3--18.3)Progesterone receptor statusPositive (≥10%)N = 1036 (66.7)38 (51.4)43 (47.8)16 (59.3)10.8 (7.5--16.6)Negative (\<10%)N = 963 (33.3)36 (48.6)46 (51.1)11 (40.7)12.0 (7.3--18.3)MissingN = 10 (0)0 (0)1 (1.1)0 (0)10.1 (10.1--10.1)HER2 receptor status[b](#tbl1fnb){ref-type="table-fn"}PositiveN = 484 (44.4)19 (25.7)19 (21.1)6 (22.2)10.0 (6.8--17.4)NegativeN = 1525 (55.6)55 (74.3)71 (78.9)21 (77.8)11.3 (7.6--16.7)Ki67[c](#tbl1fnc){ref-type="table-fn"}HighN = 1578 (88.9)60 (81.1)69 (76.7)20 (74.1)10.6 (7.3--16.9)IntermediateN = 301 (11.1)7 (9.5)15 (16.7)7 (25.9)14.7 (9.2--19.6)LowN = 110 (0)6 (8.1)5 (5.6)0 (0)10.1 (9.0--14.6)MissingN = 20 (0)1 (1.4)1 (1.1)0 (0)8.8 (7.5--10.1)Axillary lymph node statusPositiveN = 1436 (66.7)52 (70.3)61 (67.8)24 (88.9)10.8 (7.3--17.1)NegativeN = 573 (33.3)22 (29.7)29 (32.2)3 (11.1)11.7 (7.6--17.1)[^1][^2][^3]

Patients being younger, premenopausal, leaner (a lower BMI), nulliparous and/or having a history of oral contraceptive use had higher median VBD%~bilat~ at baseline in comparison to their opposites (for age and BMI, respectively, visual assessment was done of boxplot for two groups divided by the median).

In comparison to patients with less dense breasts, patients with very dense breast (BI-RADS d, N = 27) were more likely to have ER-positive tumors and to have a positive ALN status at diagnosis (89%), but VBD%~bilat~ was similar regardless of ER expression and ALN status. In total, only a few tumors had low proliferation \[Ki67, (N = 11)\]. None of the patients categorized as BI-RADS d (N = 27) had low proliferative tumors. Except for BI-RADS a, there was a trend in that denser breasts implied larger tumors.

Patients with pCR following NACT (N = 45) compared to patients without pCR (N = 155) had similar VBD%~bilat~ at all three time points ([Table 2](#tbl2){ref-type="table"}). Patients with ER-negative, PR-negative, and/or HER2-overexpressing tumors, negative ALN status, or high proliferation (Ki67) were more likely to obtain pCR irrespective of MD.Table 2Patient and tumor characteristics at diagnosis according to pathological complete response (pCR).Table 2pCR (N = 45)Non-pCR (N = 155)VBD%~bilat~ diagnosisMedian (IQR)12.4 (7.1--17.1)11.0 (7.7--16.9)Missing2 (4.4)5 (3.2)VBD%~bilat~ at T1Median (IQR)10.9 (7.1--17.0)10.7 (7.8--15.9)Missing1 (2.2)7 (4.5)VBD%~bilat~ at T2Median (IQR)11.2 (7.3--15.3)9.7 (7.7--14.7)Missing1 (2.2)6 (3.9)BI-RADS at baselinea3 (6.7)6 (3.9)b19 (42.2)55 (35.5)c17 (37.8)73 (47.1)d6 (13.3)21 (13.5)Age at diagnosisMedian (IQR)53 (46--62)53 (46--63)BMIMedian (IQR)25.5 (22.9--28.7)25.6 (22.4--28.7)Age at menarcheMedian (IQR)13 (12--14)13 (12--14)Missing1 (2.2)4 (2.6)Menopausal statusPremenopausal20 (44.4)75 (48.4)Postmenopausal25 (55.6)80 (51.6)Number of pregnanciesNone3 (6.7)16 (10.3)19 (20.0)19 (12.3)213 (28.9)63 (40.6)3+20 (44.4)57 (36.8)Any live birthNo6 (13.3)25 (16.1)Yes39 (86.7)130 (83.9)Age first birth (years)No children6 (13.3)25 (16.1)\<204 (8.9)6 (3.9)20--2918 (40.0)72 (46.5)30--3411 (24.4)33 (21.3)35+6 (13.3)15 (9.7)Missing0 (0)4 (2.6)Number of biological childrenNone6 (13.3)25 (16.1)19 (20.0)25 (16.1)219 (42.2)77 (49.7)3+11 (24.4)28 (18.1)Alcohol use once a week or more oftenYes18 (40.0)74 (47.7)No26 (57.8)81 (52.3)Missing1 (2.2)0 (0)ExerciseMore than 4 h/week11 (24.4)53 (34.2)Less than 4 h/week26 (57.8)74 (47.7)Nothing8 (17.8)26 (16.8)Missing0 (0)2 (1.3)SmokingCurrent4 (8.9)15 (9.7)Former16 (35.6)51 (32.9)Never25 (55.6)89 (57.4)Ever hormone replacement therapyYes2 (4.4)16 (10.3)No43 (95.6)139 (89.7)Oral contraceptivesCurrent0 (0)5 (3.2)Former35 (77.8)111 (71.6)Never10 (22.2)38 (24.5)Missing0 (0)1 (0.6)Tumor size at diagnosis (mm)[a](#tbl2fna){ref-type="table-fn"}Median (IQR)29 (22--38)30 (21--40)Missing1 (2.2)2 (1.3)Estrogen receptor statusPositive (≥10%)10 (22.2)111 (71.6)Negative (\<10%)35 (77.8)44 (28.4)Progesterone receptor statusPositive (≥10%)5 (11.1)98 (63.2)Negative (\<10%)40 (88.9)56 (36.1)Missing0 (0)1 (0.6)HER2 receptor status[b](#tbl2fnb){ref-type="table-fn"}Positive20 (44.4)28 (18.1)Negative25 (55.6)127 (81.9)Ki67[c](#tbl2fnc){ref-type="table-fn"}High40 (88.9)117 (75.5)Intermediate5 (11.1)25 (16.1)Low0 (0)11 (7.1)Missing0 (0)2 (1.3)Axillary node statusPositive25 (55.6)118 (76.1)Negative20 (44.4)37 (23.9)[^4][^5][^6]

The distribution of BI-RADS categories in relation to VBD%~bilat~ measured with Volpara™ at baseline is visualized in [Fig. 3](#fig3){ref-type="fig"}.Fig. 3Agreement between BI-RADS and volumetric breast density percentage (VBD%~bilat~).Fig. 3

About half of the patients (47%) decreased their VBD%~bilat~ between baseline and T1 and the corresponding percentage between baseline and T2 was 56%. Only a small temporal change in VBD%~bilat~ was seen between baseline and T1 \[median absolute decrease −0.1 (IQR -1.0 to 0.9)\] whereas a slightly more pronounced change in VBD%~bilat~ was seen between baseline and T2 \[median absolute decrease −0.5 (IQR -2.4 to 0.7)\]. A larger proportion of patients decreased their FGV~bilat~ during NACT; a total of 61% of the patients decreased their FGV~bilat~ between baseline and T1 \[median absolute decrease −3.6 (IQR -11 to 3.3)\] and 74% of the patients decreased their FGV~bilat~ between baseline and T2 \[median absolute decrease −9.6 (IQR -24 to −1.6)\] (Supplementary Material 2).

No association was seen between MD measured with Volpara™ as a static marker at T0 and T2 (VBD%~bilat~, VBD%~contra~, and FGV~bilat~) or as a dynamic marker (ΔVBD%~bilat~, ΔVBD%~contra~, and ΔFGV~bilat~) and pCR using different logistic regression models, iteratively adjusted for increasing numbers of variables ([Table 3](#tbl3){ref-type="table"}, Supplementary Material 3, and Supplementary Material 4). Furthermore, no association was found between volumetric MD and pCR for OR corresponding to 0.3 and 2.0 percentage point change in VBD%, respectively, 5% change in VBD%~bilat~, and a 1-unit change in FGV. We did not find any association between ΔVBD%~bilat~, ΔVBD%~contra~, or ΔFGV~bilat~ in the subgroup analyses based on menopausal status, ER expression, and ALN status. No trend was observed between decreasing BI-RADS categories and the likelihood of accomplishing pCR ([Table 4](#tbl4){ref-type="table"}). When using BI-RADS c as a reference, patients with both lower and higher BI-RADS categories had a higher likelihood of achieving pCR.Table 3Associations between VBD%~bilat~ and pathological complete response following neoadjuvant chemotherapy.Table 3VBD%~bilat~ exposure type, OR correspond to a 0.5 unit change in VBD%~bilat~NCasesModel 1 OR (95% CI)Model 2 OR (95% CI)Model 3 OR (95% CI)Model 3 adjusted for VBD%~bilat~ at T0 OR (95% CI)Static T0188421.00 (0.98--1.03)1.00 (0.97--1.03)1.01 (0.97--1.06)Static T2187431.00 (0.98--1.03)1.00 (0.97--1.04)1.01 (0.97--1.06)Dynamic T0-T1180411.00 (0.91--1.09)1.00 (0.92--1.08)0.96 (0.87--1.06)0.97 (0.89--1.07)Dynamic T0-T2181411.02 (0.94--1.10)1.02 (0.94--1.10)0.99 (0.91--1.08)1.00 (0.92--1.09)Dynamic T1-T2181421.02 (0.94--1.11)1.02 (0.94--1.11)1.02 (0.93--1.12)1.05 (0.95--1.16)[a](#tbl3fna){ref-type="table-fn"}[^7][^8][^9][^10]Table 4Associations between BI-RADS at diagnosis and pathological complete response following neoadjuvant chemotherapy.Table 4BI-RADSNCasesModel 1 OR (95% CI)Model 2 OR (95% CI)Model 3 OR (95% CI)a932.22 (1.49--3.30)2.32 (1.09--4.94)1.56 (0.43--5.70)b72191.59 (1.46--1.73)1.57 (1.37--1.80)1.49 (1.45--1.52)c8716d2761.27 (0.34--4.75)1.23 (0.37--4.11)2.37 (1.15--4.88)[^11][^12][^13]

4. Discussion {#sec4}
=============

In this study of 200 prospectively included BC patients, approximately three-quarters of the patients decreased their FGV~bilat~ during NACT. We found no evidence of MD as a predictive marker in the neoadjuvant setting (neither with Volpara™ nor with BI-RADS). Two previous studies \[[@bib11],[@bib12]\] found low MD at diagnosis associated with improved rates of pCR, however, both were retrospective and used a qualitative density method. Patient, tumor, and treatment characteristics were comparable across the previous two studies as well as this work (besides the single HER2-blockade in contrast to the double HER2-blockade in the current study). Another retrospective study using BI-RADS for MD assessment did not find such an association \[[@bib22]\]; however, it was based on a cohort that was different from many others---a low pCR rate (15%), suboptimal NACT (i.e., no anti-HER2 treatment to patients with HER2-overexpressing tumors), and a pCR definition that included patients with residual invasive tumor cells making comparison with other studies difficult. To the best of our knowledge, this is the first study to investigate the association between MD measured with a volumetric quantitative method and response to NACT, and investigate the rate and quantification of MD change during NACT.

It is of interest to look at the temporal association between MD and a certain intervention since changes in MD can modulate the risk, and recurrence, of BC \[[@bib2],[@bib23]\]. While a larger group of studies \[[@bib2],[@bib3],[@bib24], [@bib25], [@bib26], [@bib27], [@bib28]\] have explored the effect of endocrine treatment on MD, less is known about the association between treatment response to chemotherapy (with or without anti-HER2 therapy) and MD. A longitudinal study investigating the effect of antiestrogen treatment in the adjuvant BC setting on volumetric MD changes in a relatively large study cohort showed an annual decrease in VBD% of 0--2% \[[@bib24]\]. The corresponding number for a small study using MRI was almost 4% \[[@bib28]\].

Chen et al. further investigated the change in breast density measured with MRI during NACT in a small number of patients (N \< 45 in both studies) and showed an 11--13% reduction in percent breast density measured with MRI \[[@bib29],[@bib30]\]. Previous studies demonstrate a reduction in MD during adjuvant chemotherapy \[[@bib31], [@bib32], [@bib33]\], however only one of them provided a quantitative measure of the change in MD (−2.9 percentage points %MD). In two studies, women, predominantly younger women, with ≥10% MD reduction had a reduced risk of contralateral BC compared to women with less reduced MD \[[@bib31],[@bib33]\]. In our study, the median decline in MD during NACT was −0.5 percentage points (IQR -2.4 to 0.7) correlating to a mean decline of 4.5%. In this context, despite our relatively short period of time between first and last measurement (4.1 months, IQR 3.9--4.5 months), we should have been able to detect and quantify a potential association between density and outcome measure (pCR).

MD changes throughout a woman's life along with age and hormonal events \[[@bib34]\] with a steep decline occurring around menopausal change \[[@bib35]\]. In the NSABP B-30 trial \[[@bib36]\], the vast majority of premenopausal patients receiving adjuvant chemotherapy for BC had at least a 6-month long period of amenorrhea, and it is reasonable to expect similar proportions in our neoadjuvant-treated cohort since the patients were treated with the same combination of chemotherapy agents \[[@bib36]\]. There was a more pronounced association between MD reductions and chemotherapy in premenopausal patients in comparison to postmenopausal patients \[[@bib29],[@bib32]\]: This is likely related to a change in the hormonal milieu. Also, lobular atrophies may contribute to a MD reduction during chemotherapy \[[@bib37]\]. Thus, it is difficult to identify the underlying biological explanation for the small decline in MD seen in our study.

Bilateral and contralateral mammograms, respectively, were used for Volpara™-assessment in this study. Each Volpara™-output includes VBD%, FGV, and the absolute non-dense volume in the breast/breasts. Previous studies have shown a positive association between both FGV and VBD% and BC risk with a more pronounced association seen with VBD% \[[@bib38], [@bib39], [@bib40]\]; these data indicate the importance of the microenvironment of the non-dense breast tissue in the BC etiology. Tumor characteristics as well as host factors influence the tumor response to treatment, e.g. triple negative subtypes are known to be highly responsive to NACT \[[@bib41]\]. This motivates the adjustments in our logistic regression models. Representing the microenvironment of the surrounding breast tissue \[[@bib22]\], MD is a host factor that influences the tumor response to treatment. In terms of MD and tumor characteristics, previous studies have shown associations between higher MD and positive ALN and larger tumor size \[[@bib42], [@bib43], [@bib44]\]. In our study, approximately 70% of the patients had a positive ALN---the corresponding number for patients with very dense breasts (BI-RADS d, N = 27) was 89%. In our cohort, the median tumor size was 30.0 mm (IQR 22.0--40.0 mm) with a tendency for a larger tumor, the denser the breast. One plausible explanation contributing to the inconsistent results regarding MD as a predictive marker for pCR during NACT seen in our studies is that, in the current study, a high MD is seemingly associated with high proliferation (Ki67), which is in turn associated with a better response to NACT \[[@bib45], [@bib46], [@bib47]\]. This dilutes the previously suggested association between MD and pCR.

Several systems for pathological evaluation of the complex post-NACT response exist, and the clinical importance of residual ductal carcinoma *in situ* (DCIS) only is not yet fully understood \[[@bib48]\]. Regardless of whether residual DCIS only is considered as pCR or not, both definitions are associated with similar improved prognosis \[[@bib14]\], but the pCR rates are lower in studies using the most conservative definition. In order to include all patients with favorable prognosis, in this study, patients with only residual DCIS were categorized as having accomplished pCR.

Our study has several strengths including the prospective cohort with detailed information on patient and tumor characteristics. We used both a fully-automated volumetric density method on raw digital mammograms as well as BI-RADS categorization of processed images. Previous studies have shown different degrees of agreement and correlation \[[@bib49]\] between VBD% and BI-RADS ranging from poor to good \[[@bib50], [@bib51], [@bib52]\]. Given the proportions of the displayed patient and tumor characteristics and the ratio of pCR, we suggest that our cohort is a good reflection of the general patient group as a whole and offers external validity.

The issue of lacking consistency regarding the vendor and model of the machines must be addressed. We made no adjustment for this variable because Volpara™ has been shown to offer a consistent measurement of volumetric MD across vendors \[[@bib7],[@bib8]\]. The matter of alignment \[[@bib53]\] of mammograms that makes the amount of breast tissue similar in each image must be brought to attention when dealing with a change in MD over time. To minimize error due to alignment, each technician was repeatedly instructed to similarly position the breast each time and to capture the entire breast and not just the tumor. Thus, we believe that the principally important concept of alignment will not affect our results on a group level. No subgroup analyses based on the St. Gallen BC subtype \[[@bib54]\] were performed due to our limited number of patients. However, when stratifying on ER expression, no association was seen between volumetric MD and pCR. A larger dataset is needed to better understand the role of MD as a predictive marker during NACT in different subtypes of BC. This enables clinical applicability. Longer follow-up might be needed to demonstrate a consistent decline in MD.

5. Conclusion {#sec5}
=============

In summary, a large proportion of the patients decreased their mammographic density during neoadjuvant chemotherapy for breast cancer. We found no evidence of mammographic density, assessed with both quantitative and qualitative methods, as a predictive marker for complete pathological response in the neoadjuvant setting. Future larger studies should examine whether mammographic density holds predictive value regarding treatment with chemotherapy.
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[^1]: Tumor size (largest diameter) was retrieved from study specific radiological protocols and when the size assessments varied between the modalities, the largest measurement was used.

[^2]: If the tumor was assessed as 3+ with immunohistochemistry and/or amplified with *in situ* hybridization.

[^3]: Tumors were considered as low, intermediate or highly proliferative according to laboratory specific cutoffs (site 1: low 0--20%; intermediate 21--30%; high 31--100%, site 2: low 0--14%; intermediate 15--24%; high 25--100%) for proportion of cells staining positive for Ki67.

[^4]: Tumor size (largest diameter) was retrieved from study specific radiological protocols and when the size assessments varied between the modalities, the largest measurement was used.

[^5]: If the tumor was assessed as 3+ with immunohistochemistry and/or amplified with *in situ* hybridization.

[^6]: Tumors were considered as low, intermediate or highly proliferative according to laboratory specific cutoffs (site 1: low 0--20%; intermediate 21--30%; high 31--100%, site 2: low 0--14%; intermediate 15--24%; high 25--100%) for proportion of cells staining positive for Ki67.

[^7]: Model 1: crude analysis.

[^8]: Model 2: minimally adjusted (age, BMI, menopause, parity, HRT) analysis.

[^9]: Model 3: fully adjusted (model 2 + ER, Ki67, HER2, axillary node status and tumor size at diagnosis) analysis.

[^10]: Adjusted for VBD%~bilat~ at T1.

[^11]: Model 1: crude analysis.

[^12]: Model 2: minimally adjusted (age, BMI, menopause, parity, HRT) analysis.

[^13]: Model 3: fully adjusted (model 2 + ER, Ki67, HER2, axillary node status and tumor size at diagnosis) analysis.
